Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets

Hepatocellular carcinoma (HCC) remains a global medical burden with rising incidence due to chronic viral hepatitis and non-alcoholic fatty liver diseases. Treatment of advanced disease stages is still unsatisfying. Besides first and second generation tyrosine kinase inhibitors, immune checkpoint in...

Descripción completa

Detalles Bibliográficos
Autores principales: Neureiter, Daniel, Stintzing, Sebastian, Kiesslich, Tobias, Ocker, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626722/
https://www.ncbi.nlm.nih.gov/pubmed/31333307
http://dx.doi.org/10.3748/wjg.v25.i25.3136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626722/
https://www.ncbi.nlm.nih.gov/pubmed/31333307
http://dx.doi.org/10.3748/wjg.v25.i25.3136

Ejemplares similares